drugset / Trial / NCT01038622

Directed Immuno Nutrition by L-arginine for Critically Ill Patients

NCT01038622

Phase 4 Completed 30 enrolled Assistance Publique - Hôpitaux de Paris
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this proof-of-concept study is to demonstrate that the only administration of L-arginine, based on a suspected deficit monitored by nasal nitric oxide measurement, can improve immune functions in critically ill patients at high risk of nosocomial infection.

Timeline

Start
2009-11
Primary completion
2010-11
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator L-arginine Small molecule 200 mg/kg Other

Indications

No indication recorded.